Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
F373280
- Development stage
- Phase 2
- Lead developer
- Pierre Fabre
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
F373280 is a novel small molecule pro-drug designed to deliver docosahexaenoic acid (DHA) via oral administration. It is a monoester formed from pantothenic alcohol and DHA (molecular formula C31H49NO5). Developed by Pierre Fabre Medicament, its primary indication has been for the maintenance of sinus rhythm after electrical cardioversion in patients with persistent atrial fibrillation and chronic heart failure. Preclinical studies demonstrated that DHA reduces the duration of atrial fibrillation induced by burst pacing in animal models. The drug exerts antiarrhythmic properties by interacting with electrical and structural remodeling processes in the atria. Clinical trials have shown that after oral administration, no circulating levels of F373280 are detected—confirming its role as a prodrug for DHA[1][2][5][7].
- Other names
- panthenyl ester of docosahexaenoic acidmono ester of pantothenic alcohol and DHA
Beyond the preview
Go deeper on F373280.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on F373280.